Search results
Showing 2001 to 2050 of 4091 results for patient
NICE has a developed medtech innovation briefing on Mollii suit for spasticity .
Evidence summaries: unlicensed and off-label medicines – Integrated process statement (PMG14)
This integrated process statement has been produced to explain how 'Evidence summaries: unlicensed and off-label medicines' (ESUOMs) are developed. It provides an overview of the key process principles and describes all stages of development for ESUOMs
Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA986)
Evidence-based recommendations on lebrikizumab (Ebglyss) for treating moderate to severe atopic dermatitis in people 12 years and over.
Evidence-based recommendations on rimegepant (Vydura) for the acute treatment of migraine in adults.
NICE has developed a medtech innovation briefing (MIB) on the Secca System for faecal incontinence
Evidence-based recommendations on bronchial thermoplasty for severe asthma in adults. This involves applying heat to the inside walls of the airways.
View recommendations for HTG494Show all sections
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma in adults after 2 or more systemic therapies.
In development Reference number: GID-TA10868 Expected publication date: 15 July 2026
Our system implementation team works with organisations to help to put our guidance into practice. We work with NHS, local authority and other organisations in their area, ensuring regular interaction with our stakeholders.
Percutaneous electrical nerve stimulation for refractory neuropathic pain (HTG308)
Evidence-based recommendations on percutaneous electrical nerve stimulation for refractory neuropathic pain. This involves inserting electrode needles underneath the skin connected to a stimulator device.
View recommendations for HTG308Show all sections
Sections for HTG308
Evidence-based recommendations on autologous chondrocyte implantation using chondrosphere (Spherox) for treating symptomatic articular cartilage defects of the knee in adults.
Evidence-based recommendations on natalizumab originator (Tysabri) and biosimilar (Tyruko) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy in adults.
Focal resurfacing implants to treat articular cartilage damage in the knee (HTG635)
Evidence-based recommendations on focal resurfacing implants to treat articular cartilage damage in the knee in adults. This involves replacing the damaged area with an artificial implant.
View recommendations for HTG635Show all sections
Evidence-based recommendations on intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure from high spinal cord injuries. This involves keyhole abdominal surgery. The aim is to stimulate and possibly strengthen the diaphragm to help people breathe without a ventilator.
View recommendations for HTG679Show all sections
Evidence-based recommendations on endovascular atrial septostomy. This involves inflating a balloon passed into the heart with a catheter to try to make the hole bigger so that it does not close up completely.
View recommendations for HTG53Show all sections
Sections for HTG53
Minimally invasive sacroiliac joint fusion surgery for chronic sacroiliac pain (HTG436)
Evidence-based recommendations on minimally invasive sacroiliac joint fusion surgery for chronic sacroiliac pain in adults. This involves fixing the sacrum to the ilium using 2 or 3 metal implants.
Highly specialised technology (HST) evaluations are recommendations on the use of new and existing highly specialised medicines and treatments within the NHS in England.
Evidence-based recommendations on selinexor (Nexpovio) with dexamethasone for treating relapsed and refractory multiple myeloma after 4 or more treatments in adults.
Evidence-based recommendations on multiplex allergen testing, using ImmunoCAP ISAC 112 in people with allergy that is difficult to diagnose.
superDimension Navigation System to help diagnostic sampling of peripheral lung lesions (MIB194)
NICE has developed a medtech innovation briefing (MIB) on superDimension Navigation System to help diagnostic sampling of peripheral lung lesions .
This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and that people have access to suitable palliative care and follow-up.
Intraoperative nerve monitoring during thyroid surgery (HTG164)
Evidence-based recommendations on intraoperative nerve monitoring during thyroid surgery. This involves placing electrodes near the vocal cords to alert the surgeon when a surgical instrument comes close to either of the laryngeal nerves.
View recommendations for HTG164Show all sections
Sections for HTG164
Bimekizumab for treating moderate to severe plaque psoriasis (TA723)
Evidence-based recommendations on bimekizumab (Bimzelx) for treating moderate to severe plaque psoriasis in adults.
Laparoscopic helium plasma coagulation for the treatment of endometriosis (HTG112)
Evidence-based recommendations on laparoscopic helium plasma coagulation for the treatment of endometriosis. This involves a minimally invasive procedure used to vaporise endometrial deposits.
View recommendations for HTG112Show all sections
Sections for HTG112
Prolaris gene expression assay for assessing long-term risk of prostate cancer progression (MIB65)
NICE has developed a medtech innovation briefing (MIB) on the Prolaris gene expression assay for assessing long-term risk of prostate cancer progression
NICE has developed a medtech innovation briefing (MIB) on The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs .
Membership details, terms of reference, future meeting dates and past meeting minutes for our 4 technology appraisal committees.
Membership details, terms of reference, future meeting dates and past meeting minutes for our 4 technology appraisal committees.
U-Drain for people needing night drainage of urine or dialysis fluid (MIB95)
NICE has developed a medtech innovation briefing (MIB) on U-Drain for people needing night drainage of urine or dialysis fluid .
Evidence-based recommendations on Prontosan for treating acute and chronic wounds.
Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)
Evidence-based recommendations on certolizumab pegol (Cimzia) for treating moderate to severe plaque psoriasis in adults.
Access to a range of journals, databases and other evidence-based resources for health and social care staff in England.
Evidence-based recommendations on CorVue (Abbott Medical), HeartInsight (Biotronik), HeartLogic (Boston Scientific) and TriageHF (Medtronic) for algorithm-based remote monitoring in people with cardiac implantable electronic devices.
Urethrotech UCD for difficult or failed catheterisation (MIB116)
NICE has developed a medtech innovation briefing (MIB) on the Urethrotech UCD for difficult or failed catheterisation .
Evidence-based recommendations on pembrolizumab (Keytruda) for relapsed or refractory classical Hodgkin lymphoma in people 3 years and over.
Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM65)
Summary of the evidence on high-strength insulin glargine 300 units/ml (Toujeo) for type 2 diabetes mellitus to inform local NHS planning and decision-making
Evidence-based recommendations on PneuX to prevent ventilator-associated pneumonia.
In development Reference number: GID-TA11203 Expected publication date: 08 April 2026
Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (TA629)
Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months after treatment with rituximab or a rituximab-containing regimen in adults.
CG143/2 Question Use of low-molecular-weight heparin to treat patients with an acute painful sickle cell episode:- Are therapeutic doses...
icobrain ms for active relapsing–remitting multiple sclerosis (MIB291)
NICE has developed a medtech innovation briefing (MIB) on icobrain ms for active relapsing–remitting multiple sclerosis .
In development Reference number: GID-TA11221 Expected publication date: TBC
Extracranial to intracranial bypass for intracranial atherosclerosis (HTG452)
Evidence-based recommendations on extracranial to intracranial bypass for intracranial atherosclerosis. This involves joining a blood vessel from outside the skull to one inside the skull to bypass a narrowed or partially blocked vessel.
NICE has developed a medtech innovation briefing (MIB) on Hemosep for cell salvage .
Our associates help us to support high quality, safe, cost-effective prescribing and medicines optimisation.
NICE has developed a medtech innovation briefing (MIB) on ORA G3 to measure corneal hysteresis .
In development Reference number: GID-TA10726 Expected publication date: 13 May 2026
Etanercept and efalizumab for treating moderate to severe plaque psoriasis (TA103)
Evidence-based recommendations on etanercept (Enbrel) for treating severe psoriasis in adults.
Getting medicines to NHS patients faster with aligned decisions with the MHRA
Home News Podcasts Getting medicines to NHS patients faster with aligned decisions with the MHRA Podcasts 12 November 2025 Listen About...
Tests in secondary care to identify people at high risk of ovarian cancer (HTG453)
Evidence-based recommendations on tests in secondary care to identify people at high risk of ovarian cancer. The tests are the IOTA ADNEX model, Overa (MIA2G), RMI I (at thresholds other than 250), ROMA and IOTA Simple Rules.